Takeda Pharmaceutical Company Limited
TAK
$13.88
$0.010.07%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.24B | 30.27B | 29.58B | 29.54B | 29.69B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.24B | 30.27B | 29.58B | 29.54B | 29.69B |
| Cost of Revenue | 10.48B | 10.32B | 10.04B | 9.90B | 9.56B |
| Gross Profit | 19.77B | 19.95B | 19.54B | 19.64B | 20.13B |
| SG&A Expenses | 7.23B | 7.27B | 7.22B | 7.29B | 7.30B |
| Depreciation & Amortization | 3.61B | 3.63B | 3.60B | 3.61B | 3.60B |
| Other Operating Expenses | 993.67M | 529.65M | 1.06B | 923.95M | 823.81M |
| Total Operating Expenses | 27.00B | 26.59B | 26.85B | 26.76B | 26.22B |
| Operating Income | 3.24B | 3.68B | 2.73B | 2.78B | 3.47B |
| Income Before Tax | 1.53B | 1.77B | 306.89M | 414.37M | 1.10B |
| Income Tax Expenses | 165.33M | -152.99M | -668.77M | -601.31M | -174.50M |
| Earnings from Continuing Operations | 1.37K | 1.93K | 975.65 | 1.02K | 1.27K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.20M | -1.14M | -1.14M | -894.20K | -747.60K |
| Net Income | 1.37B | 1.93B | 974.51M | 1.01B | 1.27B |
| EBIT | 3.24B | 3.68B | 2.73B | 2.78B | 3.47B |
| EBITDA | 7.69B | 8.17B | 7.19B | 7.25B | 7.92B |
| EPS Basic | 0.87 | 1.22 | 0.62 | 0.65 | 0.81 |
| Normalized Basic EPS | 0.92 | 1.07 | 0.69 | 0.70 | 0.89 |
| EPS Diluted | 0.85 | 1.21 | 0.62 | 0.65 | 0.81 |
| Normalized Diluted EPS | 0.90 | 1.06 | 0.69 | 0.69 | 0.89 |
| Average Basic Shares Outstanding | 6.31B | 6.29B | 6.27B | 6.26B | 6.24B |
| Average Diluted Shares Outstanding | 6.35B | 6.34B | 6.29B | 6.27B | 6.25B |
| Dividend Per Share | 1.29 | 1.29 | 1.28 | 1.28 | 1.33 |
| Payout Ratio | 143.72% | 101.03% | 199.79% | 198.42% | 159.85% |